TwitterLinkedInYouTubeslideshareflickrIFPMA - Global Health Matters - BlogRSS
IFPMA Home

International Federation of Pharmaceutical Manufacturers & Associations



Select Category : 

© National Cancer Institute

About the disease

Acute myelogenous leukemia (AML) is a progressively rapid blood and bone marrow cancer that affects granulocytes or white blood cells.i, ii

Cause

Although the exact cause of AML is unclear, several risk factors exist. These include
exposure to high doses of radiation, smoking and long-term benzene exposure.i, ii

Diseaseburden

AML can affect both children and adults. Estimates suggest there are more than 13,000 new cases annually in the US alone.iii

Vaccine status

In development for the treatment of acute myelogenous leukemia.

Reference

i. US Centers for Disease Control and Prevention. Blood Cancers.

ii. US Centers for Disease Control and Prevention. Leukemia.

iii. US National Cancer Institute. What You Need To Know About™ Leukemia.

Events
Innovation
IFPMA in External Events
Resources

UPDATED! Developing World Health Partnerships Directory

The research-based pharmaceutical industry engages in a wide range of public-private partnerships...

IFPMA Code of Practice

Expanded IFPMA Code of Practice updates ethical and professional standards for interacting with...